Lawyers & Professionals

Firm Overview

Instead of trying to be everything to everybody, we’ve made a name for ourselves by delivering what our clients need most: in-depth, hands-on legal counsel throughout the financial services sector — and beyond.

Get to know us

Firm News

There’s a lot going on at Schulte — we’re wrapping up high-profile matters, welcoming talented new lawyers, speaking on issues that affect our clients, and more.

Read all about it

Pro Bono

Throughout our history, Schulte has provided comprehensive pro bono services to local and national nonprofit organizations. Today, we serve more than 50 nonprofits and work to advance a variety of social justice causes.

Learn more

Diversity and Inclusion

Inside the firm, we work hard to attract diverse, talented lawyers and encourage their career growth and advancement. And outside the office, we’re active in volunteer drives and local initiatives that support women and minorities’ professional success.

See what we’re up to

Alumni

If you’re a current or former Schulte lawyer, join our Alumni Network on LinkedIn to stay connected with old friends, make new contacts, and share your successes, ideas and insights.

Stay in touch

Social Responsibility

We take doing “good work” seriously — whether we’re talking about our high ethical standards or the way in which we foster a positive and inclusive culture for our personnel and support local communities.

See how we work

Offices

  • New York

    • 919 Third Avenue
    • New York, NY 10022
    • United States of America
      • +1 212.756.2000 Phone
      • +1 212.593.5955 Fax
  • Washington, D.C.

    • 1152 Fifteenth Street, NW, Suite 850
    • Washington, DC 20005
    • United States of America
      • +1 202.729.7470 Phone
      • +1 202.730.4520 Fax
  • London

    • One Eagle Place
    • London SW1Y 6AF
    • United Kingdom
      • +44 (0) 20 7081 8000 Phone
      • +44 (0) 20 7081 8010 Fax

From 1 March 2017, the new variation margin (‘VM’) rules for over-the-counter (‘OTC’) derivatives contained in the regulatory technical standards adopted by the European Commission (the ‘Delegated Regulation’)[1] will apply to certain European counterparties.

In anticipation of the 1 March deadline, European counterparties (and any non-EU entities, including funds, that trade with European financial institutions) are in the process of putting in place appropriate risk management procedures and compliant netting and collateral documentation to implement the new VM requirements.

To address industry concerns as to parties failing to meet the deadline, a joint-association letter (consisting of, amongst others, ISDA, SIFMA and ABA) was sent[2] to regulators and central banks requesting forbearance. In response, the European Supervisory Authorities (the ‘ESAs’) did not grant a forbearance but encouraged national competent authorities (such as the FCA in the United Kingdom) to adopt a risk-based approach in the application and enforcement of the rules. The FCA has stated[3] that it will be taking into account ‘the credibility of the plans [parties] have made’.

Legal Review of Netting and Collateral Arrangements

As well as the implementation of new VM documentation and risk management procedures, the Delegated Regulation requires each party to an OTC derivative (including investment managers on behalf of the funds they manage) to undertake an independent legal review of its exchange of collateral and netting arrangements to confirm that they are in compliance with the Delegated Regulation. In the EU, parties to OTC derivatives may be required by national competent authorities to demonstrate that a legal review has been undertaken.

Counterparties are also required to review their risk management procedures on an annual basis, which may also necessitate the legal review of any new arrangements or updates to existing margin and collateral arrangements.

Authored by Craig Stein, Ron Feldman and Anthony Lombardi.

If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


[1] Commission Delegated Regulation (EU) 2016/2251 supplementing Regulation (EU) No. 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories with regard to regulatory technical standards for risk-mitigation techniques for OTC derivative contracts not cleared by a central counterparty published on the Official Journal on 15 Nov. 2016.

[2] The joint-association letter can be viewed here.

[3] The FCA’s statement can be viewed here.


This information has been prepared by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.